Dr Reddy’s to acquire select brands from Glenmark in Russia, Ukraine

Dr. Reddy’s laboratories said on Saturday that it has tied up with Glenmark Pharmaceuticals to acquire its selective anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan.

The Hyderabad-based company has signed a deal with Glenmark with Momento Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspy and Glanspray Active (for the brand). Has made definite agreement. Dr. Reddy’s laboratories said in a statement, Ukraine) with the right to trademark, for dossiers and patent of territory.

The acquired brands represent two types of products – a combination of ametasone mono product and amazestone of amazelastine, indicated for the treatment of seasonal and perennial allergic rhinitis.

The company, however, did not disclose the financial details.

“The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important key markets for us. The most recently acquired brand, Momat Reino, has recently received OTC registration in Russia and it Will enable quick access. This product to patients, “Dr. CEO of Reddy’s Laboratories Branded Markets (India and Emerging Markets) said MV Ramna.

The acquired products will enhance the company’s strong presence in the anti-allergy segment in these countries, and will also be able to offer more comprehensive solutions to patients in the region, he said.

In a separate statement, Glenmark Pharmaceuticals Chief Commercial Officer Robert Crockart said: In line with our strategy to launch our global anti-allergy brand Ryallatis, in the markets of Russia and other CIS countries, we decided to brand the Momento Gino and its division Expansion done “

As the company awaits approval to launch Ryaltis in the Russian market, it looks forward to strengthening the respiratory franchise in the Russia / CIS region, he said.

“We are committed to respiration globally,” Crockart said.

(Only the headline and picture of this report have been reworked by Business Standard employees; the rest of the content is auto-generated from a syndicated feed.)

mail Dear reader,

Business Standard has always worked hard to provide information and commentary on events that are of interest to you and have broader political and economic implications for the country and the world. Your encouragement and continued feedback on improving our offering has only strengthened our resolve and commitment to these ideals. Even during these difficult times arising from Kovid-19, we are committed to keeping you informed and updated with relevant news, official views and critical commentary on topical issues of relevance.
However, we have a request.

As we fight the economic impact of the epidemic, we need your support even more, so that we continue to provide you with more quality content. Our subscription model has seen an enthusiastic response from many of you who have subscribed to our online content. More subscriptions to our online content can only help you achieve the goals of offering better and more relevant content. We believe in independent, fair and reliable journalism. Your support through greater membership can help us practice the journalism to which we are committed.

Support quality journalism and Subscribe to Business Standard.

Digital editor

Related Posts